Neurim Pharmaceuticals' New Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Flynn Pharma in UK and Ireland

Monday, September 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

TEL AVIV, Israel, September 25, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') and Flynn Pharma ('Flynn')

announced today a license agreement in which Flynn will obtain the exclusive marketing rights to market Neurim's newly developed Rx paediatric formulation.

Neurim and Flynn have decided to strengthen their collaboration: Flynn has been marketing

Neurim's CircadinŪ, indicated to treat the elderly for primary insomnia, in UK and Ireland since 2012. Neurim's PedPRM, targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases, is expected to be the first sleep drug approved for children.

"Flynn is a perfect match to the strategy of our paediatric sleep drug. We have trust in their ability to bring this essential treatment to children who suffer severely from sleep problems," said Nava Zisapel, CEO of Neurim Pharmaceuticals. "We are in the midst of discussions with potential partners to allow more children to benefit from this treatment in additional markets."

"We are delighted to further build and extend our Neurim partnership - their development and clinical expertise have heralded important progress in the understanding and management of insomnia," said David Fakes, CEO of Flynn Pharma.

About PedPRM 

PedPRM is a response to the unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. PedPRM met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals 

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug CircadinŪ is commercially available in more than 45 countries around the world.

Neurim has a strong and innovative product pipeline, intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

About Flynn Pharma 

Flynn Pharma (http://www.flynnpharma.com) is a privately held speciality pharmaceutical company with interests in CNS medicine in adult and paediatric patient populations, supplying branded and generic medicines in the UK, Ireland and Germany and also through export. Flynn focuses on under-served patient populations by re-discovering and re-energising tried and trusted branded pharmaceutical products.

Contact Dr. Hansjorg Jakubetz Director Corporate Business Development [email protected]

SOURCE Neurim Pharmaceuticals Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook